PT  - JOURNAL ARTICLE
AU  - Wahba, Hanan Ahmed
AU  - El-Hadaad, Hend Ahmed
TI  - Current approaches in treatment of triple-negative breast cancer
AID  - 10.7497/j.issn.2095-3941.2015.0030
DP  - 2015 Jun 01
TA  - Cancer Biology and Medicine
PG  - 106--116
VI  - 12
IP  - 2
4099  - http://www.cancerbiomed.org/content/12/2/106.short
4100  - http://www.cancerbiomed.org/content/12/2/106.full
SO  - Cancer Biol Med2015 Jun 01; 12
AB  - Triple-negative breast cancer (TNBC) is diagnosed more frequently in younger and premenopausal women and is highly prevalent in African American women. TNBC is a term derived from tumors that are characterized by the absence of ER, PgR, and HER2. So patients with TNBC do not benefit from hormonal or trastuzumab-based therapies. TNBCs are biologically aggressive, although some reports suggest that they respond to chemotherapy better than other types of breast cancer, prognosis remains poor. This is due to: shortened disease-free interval in the adjuvant and neoadjuvant setting and a more aggressive course in the metastatic setting.